Atypical Antipsychotic

Bipolar Disorder

Depressive Disorder

Schizophrenia

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-11"></a><h1>11 DESCRIPTION</h1>INVEGA SUSTENNA ®contains paliperidone palmitate. The active ingredient, paliperidone, is an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. INVEGA SUSTENNA ®contains a racemic mixture of (+)- and (-)- paliperidone palmitate. The chemical name is (9 RS)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-tetrahydro-4 H-pyrido[1,2- a]pyrimadin-9-yl hexadecanoate. Its molecular formula is C 39H 57FN 4O 4and its molecular weight is 664.89. The structural formula is: <div class="Figure"><img alt="Chemical Structure" src="invega-10.jpg"/></div>Paliperidone palmitate is very slightly soluble in ethanol and methanol, practically insoluble in polyethylene glycol 400 and propylene glycol, and slightly soluble in ethyl acetate.INVEGA SUSTENNA ®is available as a white to off-white sterile aqueous extended-release suspension for intramuscular injection in the following dose strengths of paliperidone palmitate (and deliverable volumes) of the single-dose prefilled syringes: 39 mg (0.25 mL), 78 mg (0.5 mL), 117 mg (0.75 mL), 156 mg (1.0 mL), and 234 mg (1.5 mL). The drug product hydrolyzes to the active moiety, paliperidone, resulting in dose strengths of 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg of paliperidone, respectively. The inactive ingredients are polysorbate 20 (12 mg/mL), polyethylene glycol 4000 (30 mg/mL), citric acid monohydrate (5 mg/mL), disodium hydrogen phosphate anhydrous (5 mg/mL), sodium dihydrogen phosphate monohydrate (2.5 mg/mL), sodium hydroxide (2.84 mg/mL used as an alkalizing agent to set pH at 7), and water for injection. INVEGA SUSTENNA ®is provided in a single-dose prefilled syringe (cyclic-olefin-copolymer) with a plunger stopper and tip cap (bromobutyl rubber). The kit also contains 2 safety needles (a 1 ½-inch 22 gauge safety needle and a 1-inch 23 gauge safety needle). </section>

INVEGA SUSTENNA

paliperidone

Invega

paliperidone palmitate

0.5 ML paliperidone palmitate 156 MG/ML Prefilled Syringe

0.5 ML paliperidone palmitate 156 MG/ML Prefilled Syringe [Invega]

1.5 ML paliperidone palmitate 156 MG/ML Prefilled Syringe

1.5 ML paliperidone palmitate 156 MG/ML Prefilled Syringe [Invega]

1 ML paliperidone palmitate 156 MG/ML Prefilled Syringe

1 ML paliperidone palmitate 156 MG/ML Prefilled Syringe [Invega]

0.75 ML paliperidone palmitate 156 MG/ML Prefilled Syringe

0.75 ML paliperidone palmitate 156 MG/ML Prefilled Syringe [Invega]

0.25 ML paliperidone palmitate 156 MG/ML Prefilled Syringe

0.25 ML paliperidone palmitate 156 MG/ML Prefilled Syringe [Invega]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Enroll in Patient Savings Program 

Inpatient Hospital Pharmacy Free Trial Program 

Outpatient Free Sample Program 

Alternate Site of Care Locator

About Invega Sustenna: Schizoprenia 

Side Effects: Schizoprenia 

Patient Stories: Schizoprenia 

FAQs: Schizoprenia 

Patient Resources: Schizoprenia 

Caregiver Resources: Schizoprenia 

Caregiver Communication Tips: Schizophrenia

Making an Informed Treatment Choice Worksheet

Episode Action Plan 

Treatment Recovery Plan 

Caregiver Journal

Caregiver Self-care Guide 

Instructions For Use: Schizoprenia 

About Invega Sustenna: Schizoaffective Disorder

Receiving Invega Sustenna: Schizoaffective Disorder

Patient Stories: Schizoaffective Disorder

Patient Resources: Schizoaffective Disorder

Doctor Discussion Guide: Schizoaffective Disorder

Caregiver Resouces: Schizoaffective Disorder

Caregiver Communication Tips: Schizoaffective Disorder

Instructions For Use: Schizoaffective Disorder